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Most of the cultured scleroderma ﬁbroblasts have been reported to be myoﬁbroblasts that have the ability to
express a smooth muscle actin (aSMA). It is reported that, in human lung ﬁbroblasts, aSMA is induced by trans-
forming growth factor-b (TGF-b), which requires focal adhesion kinase (FAK) phosphorylation on its Tyr-397 site. In
this study, we investigated how aSMA expression is upregulated in cultured scleroderma ﬁbroblasts. 4-amino-5-(4-
chlorophenyl)-7-(butyl)pyrazolo[3,4-d]pyrimidine, which is a pharmacologic inhibitor of FAK/Src, markedly dimin-
ished upregulated aSMA expression in scleroderma ﬁbroblasts as well as in normal ﬁbroblasts stimulated with
TGF-b. Likewise, aSMA expression was significantly reduced in sclerderma ﬁbroblasts transfected with kinase-
deﬁcient FAK mutant. FAK phosphorylation levels on Tyr-397 in scleroderma ﬁbroblasts were significantly higher
than those in normal ﬁbroblasts. Both aSMA expression and FAK phosphorylation levels in scleroderma ﬁbroblasts
were markedly diminished by the treatment with TGF-b antisense oligonucleotide. These results indicate that the
constitutive phosphorylation of FAK, which is possibly because of the autocrine TGF-b signaling, may play an
important role in aSMA expression in scleroderma ﬁbroblasts.
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Scleroderma is an autoimmune disease characterized by
the dual features of a non-inflammatory microvasculopathy
and excess extracellular matrix (ECM) accumulation in the
skin and internal organs. Fibroblasts derived from the af-
fected skin areas of scleroderma patients are considered
to be in an activated state, synthesizing the increased
amounts of connective tissue components, mainly colla-
gens I, III (LeRoy, 1974; Uitto et al, 1979; Jimenez et al,
1986) and VI (Peltonen et al, 1990), fibronectin (Fleischmajer
et al, 1981; Kinsella et al, 1989), and proteoglycans (Buck-
ingham et al, 1983). Moreover, many of the characteristics
of scleroderma fibroblasts resemble those of healthy fibro-
blasts exposed to transforming growth factor-b (TGF-b)
(Massague, 1990), suggesting that the scleroderma pheno-
type may be a result of activation by an autocrine TGF-b
loop.
Smooth muscle-actin (SMA)-positive fibroblasts (my-
ofibroblasts) are found in scleroderma and in a number of
other fibrotic conditions (Sappino et al, 1990). Ludwicka
et al (1992) have identified myofibroblasts from bronchoal-
veolar lavage of scleroderma patients. Myofibroblasts also
appear transiently in wound healing (Darby et al, 1990).
Additionally, cultured fibroblasts from affected skin of
scleroderma patients (LeRoy, 1974), from keloids (Uitto
et al, 1985), and from phenytoin-induced gingival hyperpl-
asia (Hassell et al, 1976) continue to exhibit an abnormal
phenotype even after several passages in culture. Lastly,
in situ hybridization studies showed that not all but rather
certain distinguishable fibroblasts in keloids (Kahari et al,
1988) and in affected scleroderma skin (Peltonen et al,
1991) contain high levels of collagen mRNA. Kirk et al (1995)
suggested that the myofibroblast phenotype might corre-
spond to this ‘‘activated fibroblast’’ phenotype found in
systemic sclerosis. Myofibroblasts have a high synthetic
capacity for ECM proteins (Ignotz and Massague´, 1986;
Zhang et al, 1994), growth factors/cytokines (Finlay et al,
2000), growth factor receptors (Thannickal et al, 1998), in-
tegrins (Heino et al, 1989), and oxidants (Thannickal and
Fanburg, 1995).
The presence of myofibroblasts appears to be a con-
sistent finding in the pathology of human fibrotic diseases
involving diverse organ systems such as the lung, liver,
and kidney (Border and Noble, 1994). Thus, persistent my-
ofibroblast proliferation and/or survival represent a patho-
logic repair process that can result in aberrant architectural
remodeling of tissues associated with end-stage fibrosis
and organ failure.
The focal adhesion kinase (FAK) is a protein tyrosine
kinase (PTK) that is regulated by multiple extracellular stim-
uli (Schaller et al, 1994; Schwartz et al, 1995). Cell adhesion
to the ECM proteins, e.g., fibronectin or collagen, via their
receptors, the integrins (Hynes, 1992), induces the tyrosine
phosphorylation of FAK and stimulation of its enzymatic
Abbreviations: aSMA, a smooth muscle actin; ECM, extracellular
matrix; FAK, focal adhesion kinase; PP2, 4-amino-5-(4-chlorophe-
nyl)-7-(butyl)pyrazolo[3,4-d]pyrimidine; RGD, Arg–Gly–Asp; RGE,
Arg–Gly–Glu; TGF-b, transforming growth factor-b
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activity (Burridge et al, 1992; Guan and Shalloway, 1992;
Hanks et al, 1992; Kornberg et al, 1992; Lipfert et al, 1992).
Treatment of cells with a number of agents including growth
factors, neuropeptides, and lysophosphatidic acid can in-
duce the phosphorylation of FAK on tyrosine (Zachary et al,
1992; Kumagai et al, 1993; Sinnett-Smith et al, 1993; Barry
and Critchley, 1994; Chrzanowska-Wodnicka and Burridge,
1994; Matsumoto et al, 1994; Polte et al, 1994; Rankin and
Rozengurt, 1994; Ridley and Hall, 1994; Seufferlein and
Rozengurt, 1994). Thus multiple stimuli, acting on distinct
cell surface receptors that trigger discrete cytoplasmic
signaling pathways, converge to induce a common re-
sponse, the tyrosine phosphorylation of FAK. Like other
PTK, tyrosine phosphorylation of FAK plays an important
role in regulating signaling. Six tyrosine residues within FAK
have been identified as sites of phosphorylation. The major
site of autophosphorylation is Tyr 397 (Chan et al, 1994;
Schaller et al, 1994; Calalb et al, 1995; Eide et al, 1995).
Moreover, Thannickal et al (2003) showed that tyrosine
phosphorylation of FAK at Tyr 397 site is involved in my-
ofibroblast differentiation induced by TGF-b using human
lung fibroblasts. This study was undertaken to examine a
possible role of autocrine TGF-b signaling and FAK phos-
phorylation in myofibroblast differentiation of scleroderma
fibroblasts.
Results
Comparison of levels of aSMA expression between cul-
tured normal and scleroderma ﬁbroblasts We compared
the constitutive aSMA expression levels between normal
and scleroderma fibroblasts by immunoblotting. Consistent
with previous reports (Peltonen et al, 1991), scleroderma
fibroblasts expressed increased levels of aSMA protein
(9.9-fold. Fig 1). Six separate lanes for normal and
scleroderma fibroblast cultures represent six separate pri-
mary isolates from different individuals.
Effect of a pharmacologic FAK/Src inhibitor on the
TGF-b-mediated aSMA protein upregulation in normal
ﬁbroblasts and on the constitutive overexpression of
aSMA protein in scleroderma dermal ﬁbroblasts We
investigated the effect of 4-amino-5-(4-chlorophenyl)-7-
(butyl)pyrazolo[3,4-d]pyrimidine (PP2), which is a phar-
macologic FAK/Src inhibitor, and TGF-b on the expression
of aSMA in normal and scleroderma dermal fibroblasts by
immunoblotting. As shown in Fig 2A, in normal fibroblasts,
PP2 slightly reduced the basal level of aSMA expression
and TGF-b induced upregulation of aSMA expression (4.2-
fold), which was inhibited by PP2. In contrast, PP2 signif-
icantly reduced the basal level of aSMA expression in
scleroderma fibroblasts. The inhibitory effect of PP2 on
aSMA expression induced by TGF-b was concentration-
dependent both in normal and scleroderma fibroblasts.
Next, we examined the effect of PP2 and TGF-b on the
expression of aSMA in normal and scleroderma dermal fib-
roblasts by immunofluorescence (Fig 2B). The majority of
untreated normal fibroblasts were smaller and expressing
less amounts of aSMA than that of untreated scleroderma
fibroblasts. PP2 blocks cell hypertrophy and formation of
actin stress fibers induced by TGF-b1 or observed in un-
treated scleroderma fibroblasts. The treatment of PP2 had
little effect on the size or basal aSMA expression levels in
normal fibroblasts, whereas it markedly reduced the size
and basal aSMA expression in scleroderma fibroblasts. The
stimulation with TGF-b turned normal fibroblasts into larger
cells expressing much more aSMA, which looked like
scleroderma fibroblasts. But, the treatment with TGF-b
brought about little change in scleroderma fibroblasts. PP2
had an inhibitory effect on the size and aSMA expression
levels both in normal and scleroderma fibroblasts stimulat-
ed with TGF-b. These findings suggested that the upreg-
ulation of aSMA expression observed in normal fibroblasts
treated with TGF-b or in untreated scleroderma fibroblasts
requires FAK activation.
Comparison of FAK phosphorylation levels between
cultured normal and scleroderma ﬁbroblasts We exam-
ined the basal phosphorylation levels of FAK (Tyr-397 site) in
cultured normal and scleroderma dermal fibroblasts by
immunoblotting using a site-specific antibody. As shown in
Fig 3, the basal phosphorylation levels of FAK in scler-
oderma fibroblasts were significantly higher than those in
normal fibroblasts (1.8-fold). Four separate lanes for normal
and scleroderma fibroblast cultures represent four separate
primary isolates from different individuals.
Figure1
Comparison of levels of a smooth muscle actin (aSMA) expression
between cultured normal and scleroderma fibroblasts. Whole-cell
lysates for aSMA were electrophoresed through a 10% polyacrylamide
gel, transferred to a nitrocellulose membrane, and probed with anti-
aSMA antibodies. After stripping, the levels of b-actin were determined
by anti-b-actin antibody. One representative of five independent ex-
periments is shown in the upper panel. Six separate lanes for normal
and scleroderma fibroblast cultures represent six separate primary
isolates from different individuals. The aSMA levels quantitated by
scanning densitometry densitometry and corrected for the levels of b-
actin in the same samples are shown relative to the levels in normal
fibroblasts (1.0). Data are expressed as the mean  SD of five inde-
pendent experiments (lower panel). po0.05, as compared with the
value in normal fibroblasts.
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TGF-b induces FAK phosphorylation on Tyr-397 site in
normal ﬁbroblasts We investigated whether TGF-b induc-
es FAK phoshorylation on Tyr-397 site using normal dermal
fibroblasts. Like a previous report using lung fibroblasts,
TGF-b induced FAK phosphorylation in dermal fibroblasts in
a time-dependent manner (2.2-fold, Fig 4). FAK phosphor-
ylation level started to increase about 3 h after the stimulation
and sustained for a relatively long duration (about 24 h).
Transfection of kinase-deﬁcient FAK diminished both
TGF-b-mediated aSMA protein upregulation in normal
ﬁbroblasts and constitutive overexpression of aSMA
protein in scleroderma dermal ﬁbroblasts To further
confirm that phosphorylation of FAK, especially at Tyr-397
site, is required for the upregulated expression of aSMA
observed in the TGF-b stimulated normal fibroblasts and
untreated scleroderma fibroblasts, both normal and scler-
oderma fibroblasts were transfected with a mutant FAK
(Y397F-FAK) or an empty vector, and aSMA expression was
determined by immunoblotting. In normal fibroblasts trans-
fected with Y397F-FAK, the basal level of aSMA expression
was almost the same as that of mock transfectants,
although aSMA expression in response to TGF-b1 was
significantly diminished in a concentration-dependent man-
ner (Fig 5). In scleroderma fibroblasts transfected with
mutant FAK (Y397F-FAK) without stimulation, the basal level
of aSMA expression was significantly diminished (Fig 5).
Figure 2
The effect of 4-amino-5-(4-chlorophenyl)-7-(butyl)pyrazolo[3,4-
d]pyrimidine (PP2), a pharmacologic FAK/Src inhibitor, and trans-
forming growth factor-b (TGF-b) on a smooth muscle actin (aSMA)
expression in cultured normal and scleroderma fibroblasts. (A)
Human dermal fibroblasts were serum-starved for 24 h and pre-treated
with the indicated doses of PP2 for 1 h prior to the addition of 2 ng per
mL of TGF-b for 24 h. Cell lysates were then obtained and subjected to
SDS-PAGE followed by immunoblotting with antibodies against aSMA
and b-actin. Levels of b-actin are shown as a loading control. The
bands shown represent two primary isolates from one normal donor
and one scleroderma patient. One representative of five independent
experiments is shown in the upper panel. The aSMA levels quantitated
by scanning densitometry and corrected for the levels of b-actin in the
same samples are shown relative to the level in untreated normal cells
(1.0). Data are expressed as the mean  SD of five independent ex-
periments (lower panel). po0.05, as compared with the value in un-
treated scleroderma fibroblasts. #po0.05, as compared with the value
in untreated normal fibroblasts. (B) The shape and aSMA expression
were investigated with immunofluorescence analysis using human nor-
mal and scleroderma fibroblasts as described in Materials and Meth-
ods. PP2 blocks cell hypertrophy and formation of actin stress fibers
induced by TGF-b1 or observed in untreated scleroderma fibroblasts.
a, untreated normal fibrolblasts. b, normal fibroblasts treated with PP2
(20 mM). c, normal fibroblasts treated with 2 ng per mL TGF-b1. d,
normal fibroblasts treated with both PP2 (20 mM) and 2 ng per mL TGF-
b1. e, untreated scleroderma fibroblasts. f, scleroderma fibroblasts
treated with PP2 (20 mM). g, normal fibroblasts treated with 2 ng per mL
TGF-b1. h, scleroderma fibroblasts treated with both PP2 (20 mM) and 2
ng per mL TGF-b1.
Figure3
Comparison of focal adhesion kinase (FAK) phosphorylation levels
between cultured normal and scleroderma fibroblasts. Whole-cell
lysates were electrophoresed through a 10% polyacrylamide gel,
transferred to a nitrocellulose membrane, and probed with anti-site-
specific p-FAK (Try 397) antibodies. After stripping, total levels of FAK
were determined by anti-FAK antibody. One representative of five in-
dependent experiments is shown in the upper panel. Four separate
lanes for normal and scleroderma fibroblast cultures represent four
separate primary isolates from different individuals. The p-FAK levels
quantitated by scanning densitometry densitometry and corrected for
the levels of total FAK in the same samples are shown relative to the
levels in normal fibroblasts (1.0). Data are expressed as the mean  SD
of five independent experiments (lower panel). po0.05, as compared
with the value in normal fibroblasts.
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Together, these results indicate that the autophosphorylat-
ion of FAK on Tyr-397 is required for the myofibroblast dif-
ferentiation induced by TGF-b1 in normal fibroblasts, and
that observed in scleroderma fibroblasts.
The treatment with TGF-b1 antisense oligonucleotide
significantly reduced the level of aSMA expression and
FAK phosphorylation on Tyr-397 in scleroderma ﬁbro-
blasts To examine the possibility that the upregulated levels
of aSMA expression and FAK phosphorylation on Tyr-397 in
scleroderma fibroblasts are because of the autocrine TGF-b
signaling, we investigated the effect of TGF-b1 antisense
oligonucleotide on the levels of aSMA expression and FAK
phosphorylation on Tyr-397. As shown in Fig 6A, the treat-
ment with TGF-b1 antisense oligonucleotide did not signif-
icantly reduce aSMA expression in normal fibroblasts. In
contrast, TGF-b1 antisense oligonucleotide markedly re-
duced aSMA expression in scleroderma fibroblasts. The
treatment with TGF-b1 sense oligonucleotide had no effect
on aSMA expression. The FAK phosphorylation levels in
scleroderma fibroblasts were significantly diminished by the
treatment with TGF-b1 antisense oligonucleotide, whereas
those in normal fibroblasts decreased only slightly (Fig 6B).
These results imply that the upregulated levels of aSMA ex-
pression and FAK phosphorylation on Tyr-397 in scleroderma
fibroblasts are because of the autocrine TGF-b signaling.
The treatment with RGD (Arg–Gly–Asp) containing
peptide significantly reduced aSMA expression in
scleroderma ﬁbroblasts Previous studies showed that
TGF-b-mediated upregulation of aSMA expression is at
least partially through the interactions between ECM and
integrins (Thannickal et al, 2003). We examined whether
RGD-containing peptide, which is an antagonist of integrin
function, could reduce aSMA expression in scleroderma
fibroblasts that have been reported to overexpress both
ECM and integrins (Fleischmajer et al, 1981; Kinsella et al,
1989; Asano et al, 2004). As shown in Fig 7, the treatment
with RGD-containing peptide did not significantly reduce
aSMA expression in normal fibroblasts. In contrast, RGD-
containing peptide markedly reduced aSMA expression
in scleroderma fibroblasts. The treatment with RGE (Arg–
Gly–Glu)-containing peptide had no inhibitory effect on
aSMA expression.
Figure 4
Transforming growth factor-b (TGF-b) induces focal adhesion kin-
ase (FAK) phosphorylation on Tyr-397 site in normal dermal fibro-
blasts. Normal dermal fibroblasts were serum-starved for 24 h and
incubated for the indicated time in the presence of 2 ng per mL TGF-b.
Then, FAK phosphorylation levels were determined in the same manner
as in Fig 4. One representative of five independent experiments is
shown in the upper panel. The p-FAK levels quantitated by scanning
densitometry densitometry and corrected for the levels of total FAK in
the same samples are shown relative to the levels in untreated normal
fibroblasts (1.0). Data are expressed as the mean  SD of five inde-
pendent experiments (lower panel). po0.05, as compared with the
value in untreated normal fibroblasts.
Figure5
Transfection of kinase-deficient focal adhesion kinase (FAK) di-
minished both the transforming growth factor-b (TGF-b)-mediated
a smooth muscle actin (aSMA) protein upregulation in normal fib-
roblasts and the constitutive overexpression of aSMA protein in
scleroderma fibroblasts. Human dermal fibroblasts were transiently
transfected with either empty vector or with the indicated doses of
kinase-deficient FAK mutant (Y397F-FAK, substitution of Phe for Tyr-
397). After incubation overnight, the transfected cells were either treat-
ed or untreated with 2 ng per mL TGF-b1 for 48 h. Cell lysates were
obtained and subjected to SDS-PAGE followed by immunoblotting with
antibodies against aSMA and b-actin. Levels of b-actin are shown as a
loading control. The bands shown represent two primary isolates from
one normal donor and one scleroderma patient. One representative
result of five independent experiments is shown. The aSMA levels
quantitated by scanning densitometry densitometry and corrected for
the levels of b-actin in the same samples are shown relative to the level
in mock-transfected normal cells (1.0). Data are expressed as the
mean  SD of five independent experiments (lower panel). po0.05,
as compared with the value in untreated scleroderma fibroblasts.
#po0.05, as compared with the value in mock-transfected normal fib-
roblasts.
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Discussion
It is well established that most cultured scleroderma fibro-
blasts express aSMA even after several passages. Little is
known, however, about how cultured scleroderma fibro-
blasts maintain the expression of aSMA.
aSMA can be induced by exogenous TGF-b in cultured
normal fibroblasts. Therefore, there is a good possibility
that the autocrine TGF-b loop contributes to the mainte-
nance of aSMA expression in scleroderma fibroblasts.
In this study, we showed that TGF-b1 antisense oligonuc-
leotide significantly reduced the level of aSMA expres-
sion, which seems to support the possibility described
above.
A previous report suggested that aSMA expression was
increased through the interaction between integrins and
ECM, especially fibronectin, via phosphorylation of FAK
(Thannickal et al, 2003). Both integrins and fibronectin have
been reported to be upregulated in scleroderma (Fleisch-
majer et al, 1981; Kinsella et al, 1989; Asano et al, 2004). We
assumed that increased interaction between integrins and
ECM leads to overexpression of aSMA in scleroderma fib-
roblasts through the enhancement of FAK phosphorylation.
In this study, we showed that FAK phosohorylation is con-
stitutively upregulated in scleroderma fibroblasts and that a
dominant-negative mutant form of FAK markedly reduced
aSMA expression in scleroderma fibroblasts. In addition,
we demonstrated that RGD-containing peptide, which is
an antagonist of integrin function, significantly reduced
aSMA expression in scleroderma fibroblasts. All of these
Figure 6
The treatment with transforming growth factor-b1 (TGF-b1) anti-
sense oligonucleotide significantly reduced the levels of a smooth
muscle actin (aSMA) expression and focal adhesion kinase (FAK)
phosphorylation on Tyr-397 in scleroderma fibroblasts. (A) The effect
of TGF-b1 antisense oligonucleotide on aSMA protein expression was
investigated by immunoblotting (upper panel). Normal and scleroderma
fibroblasts were treated with TGF-b1 antisense oligonucleotide for 48 h.
The bands shown represent four primary isolates from two normal do-
nors and two scleroderma patients. One representative of five inde-
pendent experiments is shown. The aSMA levels quantitated by
scanning densitometry densitometry and corrected for the levels of b-
actin in the same samples are shown relative to those in normal fibro-
blasts treated with sense oligonucleotide (1.0). Data are expressed as
the mean  SD of five independent experiments (lower panel). po0.05
versus control cells treated with TGF-b1 sense oligonucleotide. (B) The
effect of TGF-b1 antisense oligonucleotide on FAK phosphorylation lev-
els was investigated by immunoblotting (upper panel). Normal and
scleroderma fibroblasts were treated with TGF-b1 antisense oligonuc-
leotide for 48 h. The bands shown represent four primary isolates from
two normal donors and two scleroderma patients. One representative of
five independent experiments is shown. The p-FAK levels quantitated by
scanning densitometry densitometry and corrected for the levels of total
FAK in the same samples are shown relative to those in normal fibro-
blasts treated with sense oligonucleotide (1.0). Data are expressed as
the mean  SD of five independent experiments (lower panel). po0.05
versus control cells treated with TGF-b1 sense oligonucleotide.
Figure7
The treatment with RGD (Arg–Gly–Asp)-containing peptides sig-
nificantly reduced a smooth muscle actin (aSMA) expression in
scleroderma fibroblasts. The effect of RGD-containing peptides on
aSMA protein expression was investigated by immunoblotting (upper
panel). Normal and scleroderma fibroblasts were treated with RGD- or
RGE (Arg–Gly–Glu)-containing peptides for 48 h. The bands shown
represent four primary isolates from two normal donors and two
scleroderma patients. One representative of five independent experi-
ments is shown. The aSMA levels quantitated by scanning densitome-
try densitometry and corrected for the levels of b-actin in the same
samples are shown relative to those in normal fibroblasts treated with
RGE-containing peptides (1.0). Data are expressed as the mean  SD
of five independent experiments (lower panel). po0.05 versus control
cells treated with RGE-containing peptides.
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findings support the notion that the interaction between
integrins and ECM leads to overexpression of aSMA in
scleroderma fibroblasts through the enhancement of FAK
phosphorylation.
In conclusion, we demonstrated that the autocrine TGF-b
signaling and the interaction between integrins and ECM
contribute to the upregulation of aSMA expression in cul-
tured scleroderma fibroblasts. These results suggested that
various kinds of agents that inhibit autocrine TGF-b signa-
ling or the interaction between integrins and ECM could be
used as a therapeutic intervention for scleroderma by turn-
ing back scleroderma fibroblasts abnormally overexpress-
ing aSMA into approximately normal fibroblasts less
expressing aSMA.
Materials and Methods
Reagents Recombinant human TGF-b1 was obtained from R&D
Systems (Minneapolis, Minnesota). PP2 was from Calbiochem (La
Jolla, California). Anti-b-actin, anti-aSMA antibodies, synthetic
RGD/RGE containing peptides were purchased from Sigma (St.
Louis, Missouri). The luciferase assay kit was purchased from
Promega (Madison, Wisconsin). Phosphorylation-specific antibody
to Tyr-397-FAK was from BIOSOURCE International (Carmillo, Cal-
ifornia). Antibody for FAK was purchased from Upstate Biotech-
nology (Lake Placid, New York). FuGENE 6 was obtained from
Roche Diagnostics (Indianapolis, Indiana).
Cell cultures Human dermal fibroblasts were obtained by skin
biopsy from the affected areas (dorsal forearm) of eight patients
with diffuse cutaneous scleroderma and o2 y of skin thickening
(Ihn et al, 2001). Control fibroblasts were obtained by skin biopsy
from eight healthy donors. Institutional approval and written in-
formed consent were obtained from all subjects. The study was
conducted according to the Declaration of Helsinki principles.
Control donors were matched with each scleroderma patient for
age, sex, and biopsy site, and control and patient samples were
processed in parallel. Primary explant cultures were established in
25-cm2 culture flasks in modified eagle’s medium (MEM) with 10%
fetal calf serum (FCS), 2 mM L-glutamine, and 50 mg per mL amp-
hotericin. Fibroblast cultures independently isolated from different
individuals were maintained as monolayers at 371C in 95% air, 5%
CO2, and studied between the third and sixth subpassages.
Cell lysis and Immunoblotting Fibroblasts were grown to sub-
confluence in MEM with 10% FCS. After 24 h serum starvation,
cells were solubilized in lysis buffer (1% Triton X-100 in 50 mM Tris-
HCl (pH 7.4), 150 mM NaCl, 3 mM MgCl2, 1 mM CaCl2 containing
10 mg per mL leupeptin, pepstatin, aprotinin, 1 mM PMSF, and
1 mM Na3VO4). The loading amount was adjusted by the protein
concentrations of cell lysate determined by a Bio-Rad protein as-
say (Hercules, California), as recommended by the manufacturer.
Proteins were subjected to SDS-polyacrylamide gel elect-
rophoresis and transferred to nitrocellulose membranes. Mem-
branes were incubated overnight with anti-aSMA antibody, anti-
FAK antibody, or anti-pFAK antibody (1:1000 dilution), washed, and
incubated with horseradish peroxidase-conjugated secondary an-
tibodies for 60 min. After washing, visualization was performed by
enhanced chemiluminescence (Amersham Pharmacia Biotech,
Arlington Heights, Illinois). As a loading control, immunoblotting
was also performed using antibodies against b-actin.
Immunoﬂuorescence Immunofluorescence analysis was per-
formed as described previously (Ihn and Tamaki, 2002). In brief,
normal and scleroderma fibroblasts were cultured in four-well tis-
sue culture chamber slides. After cells were placed under condi-
tions of serum starvation for 24 h and treated with 2 ng per mL
TGF-b for an additional 48 h, the medium was removed and the
cells were washed with PBS and fixed in 3.7% formaldehyde/PBS
for 10 min. After two washes with PBS, cells were incubated for 30
min in PBS containing 10% FBS. Cells were permeabilized with
0.5% Triton-X. An antibody against aSMA was added and the
slides were incubated for 1 h at 371C. After three washes, a flu-
orescein-conjugated secondary antibody was added and the
slides were incubated for 1 h at 371C.
Treatment of dermal ﬁbroblasts with TGF-b1 antisense
oligonucleotides We used a TGF-b1 18-mer antisense oligonuc-
leotide (GAGGGCGGCATGGGGAGG), which overlaps the promot-
er and transcriptional start site of the TGF-b1 gene. This same
sequence, which is specific for the TGF-b1 isoform, has been
found to be sufficient to block TGF-b1 transcription in vitro (Fa-
langa et al, 1998; Ihn et al, 2001) and in vivo (Brunet et al, 1995). A
sense oligonucleotide was also used as control.
Fibroblasts were grown to confluence and the culture medium
was removed, washed with MEM to remove excess TGF-b1, and
replaced with serum-free MEM. Then antisense or sense TGF-b1
oligonucleotide was added, and cell lysates were obtained 48 h
later.
Plasmids The mammalian expression plasmid pKH3 encoding
mutant FAK (substitution of Phe for Tyr-397; Y397F-FAK) was a
kind gift from Dr Hong-Chen Chen (Institute for Biochemistry, Na-
tional Chung Hsing University, Taiwan) and has been described
previously (Chen et al, 1996). Plasmids used in transient transfect-
ion assays were purified twice on CsCl gradients, as described
previously. At least two different plasmid preparations were used
for each experiment.
Transient transfection Fibroblasts were grown to 50% conflu-
ence in 100 mm dishes. After 24 h incubation with serum-free
medium, cultures were transfected with the indicated doses of
empty vector or kinase-deficient FAK mutant (Ihn et al, 2002).
Statistical analysis Data presented as bar graphs are the
means  SD of at least three independent experiments. Statisti-
cal analysis was performed by the Mann–Whitney U test. p values
less than 0.05 were considered significant.
We thank Dr Hong-Chen Chen (Institute for Biochemistry, National
Chung Hsing University, Taiwan) for providing the FAK-Y397F mutant
plasmid.
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